Skip to content

A multi-center Randomized Controlled Trial of superior formula of Jianpi Huayu Jiedu for gastric precancerous lesions

Disease-Zheng integrated study of the progressing pattern of Gastric

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000375
Enrollment
Unknown
Registered
2024-09-04
Start date
2021-04-17
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Precancerous Lesion

Interventions

control group:Chinese herbal granules placebo 1 sachet/dose 1 time/day. Oral folic acid tablets 10mg/dose 3 times/day.

Sponsors

Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Chronic atrophic gastritis was diagnosed by histopathology and conformed to the diagnostic criteria of traditional Chinese medicine; the age was = 18 years old and < 70 years old; all the HP positive patients had received anti-HP treatment and were enrolled in the HP negative group; those who had not received other treatment in the last month and did not participate in other new drug clinical trials; voluntarily signed informed consent form; passed the hospital ethics review.

Exclusion criteria

Exclusion criteria: Misdiagnosed as chronic atrophic gastritis; complicated with gastric ulcer gastric hemorrhage esophageal cancer and other digestive tract tumors; severe heart brain liver kidney lung and other diseases; major organ damage dysfunction; complicated with hematological diseases endocrine tumors autoimmune diseases; serious diseases need rescue surgery and other treatment can not continue this experiment; serious mental and nervous system diseases. People who are addicted to drugs such as aspirin and opiates; those who have bad habits such as alcoholism; those who need isolation treatment for severe infectious diseases; have contraindications or no history of drug allergy to useful drugs are allergic to the drugs in this study; are pregnant or lactating; those who are positive for HP infection or are ineffective by anti-HP treatment; take proton pump inhibitors H2 receptor antagonists acid inhibitors quinolones antibiotics or bismuth agents within one week. Experts from other research groups agree that it is not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Histopathological evaluation;

Secondary

MeasureTime frame
Criteria for judging the curative effect of TCM syndromes;Efficacy of clinical symptoms;

Countries

China

Contacts

Public ContactXiongwen Wang; Huafeng Pan

Guangzhou University of Chinese Medicine/ Science and Technology Innovation CenterGuangzhou University of Chinese Medicine

gzphf@gzucm.edu.cn+86 20 3935 8328

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026